anti-HLA-A2 CAR Treg-cell therapy (Kyoto University/Takeda Pharmaceutical)

N/A

Report date: 2025/01/26 19:06:31

Base Information

Drug Nameanti-HLA-A2 CAR Treg-cell therapy (Kyoto University/Takeda Pharmaceutical)
Drug Alias NameiPSC-derived HLA-A2 CAR-transduced FOXP3+ T cells
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionHLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators
TargetsHLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsInflammationGraft vs Host DiseaseAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKyoto University
China Registration ClassN/A

Develop Information

Active CompaniesKyoto UniversityTakeda Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsInflammationGraft vs Host DiseaseAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A